Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasm Metastasis × tucatinib × Clear all

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Brain Neoplasms 2 Stomach Neoplasms 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 36 Nivolumab 20 Gemcitabine 18 Paclitaxel 17 Cyclophosphamide 17 Capecitabine 16 fludarabine 11 aldesleukin 11 Ipilimumab 11 130-nm albumin-bound paclitaxel 10 Docetaxel 9 Trastuzumab 8 Albumin-Bound Paclitaxel 8 Radiosurgery 7 Interleukin-2 7 Biopsy 7 Bevacizumab 7 fludarabine phosphate 6 Temozolomide 6 Specimen Handling 6 Irinotecan 6 Fluorouracil 6 Cisplatin 6 Cetuximab 6 Carboplatin 6 avelumab 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Magnetic Resonance Spectroscopy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04896320 2023-06-22

2019-101826

Providence Health & Services

Phase 1/2 Withdrawn

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡